NCT02689336 Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors Status WITHDRAWN Phase PHASE2
NCT02685605 Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT02681705 Radiation Therapy and Combination Chemotherapy for Medulloblastoma Status UNKNOWN Phase PHASE2
NCT02672241 Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children Status UNKNOWN Phase PHASE2
NCT02667587 An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) Status COMPLETED Phase PHASE3
NCT02663440 Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme Status UNKNOWN Phase PHASE2
NCT02661282 Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma Status COMPLETED Phase PHASE1/PHASE2
NCT02655601 Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 Status COMPLETED Phase PHASE1/PHASE2
NCT02654106 Stereotactic Radiotherapy Plus Temozolomide for Refractory Brain Metastases Status COMPLETED Phase PHASE2
NCT02617589 An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) Status COMPLETED Phase PHASE3
NCT02605811 Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer Status UNKNOWN Phase PHASE2
NCT02599090 Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma Status WITHDRAWN Phase PHASE2
NCT02596828 Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma Status COMPLETED Phase PHASE2
NCT02595424 Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02590263 Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma Status COMPLETED Phase PHASE1/PHASE2
NCT02573324 A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification Status COMPLETED Phase PHASE3
NCT02530502 Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma Status TERMINATED Phase PHASE1
NCT02511132 A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma Status COMPLETED Phase PHASE2
NCT02510950 Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma Status TERMINATED Phase PHASE1
NCT02507232 Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas Status TERMINATED Phase EARLY_PHASE1